Skip to content

    Epilepsy Health Center

    Font Size

    Study: Low Birth Defect Risk From Newer Epilepsy Drugs

    Researchers Say Findings Are Reassuring, but Data on Topamax Inconclusive
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    May 17, 2011 -- Use of newer antiseizure drugs during the first trimester of pregnancy was not associated with an increased risk for major birth defects in one of the largest studies ever to examine the issue.

    The finding can be seen as reassuring to women of childbearing age who take the newer epilepsy drugs. But it had one major limitation: It did not include many women who took the drug Topamax (topiramate).

    Back in March, the FDA warned that use of Topamax early in pregnancy was associated with an increased risk for cleft lip and cleft palate in newborns, citing new drug registry data suggesting a 16-fold increase in risk.

    Most of the women in the new study who took an antiseizure drug took Lamictal (lamotrigine), and their birth defect risk was just slightly higher than women who took no antiseizure drugs.

    Just over 100 of the 800,000 women included in the Danish registry study took Topamax, researcher Anders Hviid, MSc, of Copenhagen’s Statens Serum Institut tells WebMD.

    The study appears in tomorrow’s Journal of the American Medical Association.

    “We cannot conclude anything or make any recommendations on [Topamax], based on this study,” he says.

    Birth Defects Rare With Newer Drugs

    As many as one in 200 pregnant women take antiseizure drugs for epilepsy and, increasingly, for other conditions like migraines and bipolar disorder.

    The risk of birth defects with the second-generation drugs that began appearing in the early 1990s is clearly much lower than for older antiseizure drugs like Depakote (valproic acid). But studies examining their safety during early pregnancy or at conception are limited.

    The Danish study included data on 837,795 live births occurring in that country between January 1996 and September 2008, including 1,532 women who took a second-generation antiseizure drug during their first trimester.

    Just over a thousand women took Lamictal, about 400 took Trileptal (oxcarbazepine), about 100 took Topamax, and close to 60 each took Neurontin (gabapentin) or Keppra (levetiracetam). Some of the women took more than one drug.

    Major birth defects occurred in 3.2% of infants exposed to one of the drugs early in development, compared to 2.4% of babies who were not exposed to any of the drugs.

    A total of 4.6% of women who took Topamax and 3.7% to 4% of women who took Lamictal delivered babies with major birth defects.

    Today on WebMD

    human head and brain waves
    Causes, symptoms, and treatments.
    Grand mal seizure
    How is each one different?
    marijuana plant
    CBD, a plant chemical, may cut down seizures.
    prescription bottle
    Which medication is right for you?
    Seizures Driving
    Questions for Doctor Epilepsy
    Graces Magic Diet
    Pills spilling from bottle in front of clock
    first aid kit
    Caring Child Epilepsy
    Making Home Safe
    epilepsy monitoring